|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
1/2013
vol. 115 abstract:
Original paper
Botulinum toxin injection as primary treatment for esotropia in patients with cerebral palsy
Malgorzata Mrugacz
1
,
Wojciech Kułak
2
,
Alina Bakunowicz-Łazarczyk
1
,
Artur Bossowski
3
Klinika Oczna 2013, 115 (1): 13-14
Online publish date: 2013/03/28
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Introduction
Botulinum toxin type A is a potent neurotoxin that blocks the release of acetylocholine at the neuromuscular junction of cholinergic nerves. Cerebral palsy is cause of ocular disorders. There is an increased presence of strabismus, refractive errors, and reduced visual acuity. The purpose of this study was to assess the efficacy of botulinum toxin injection in the treatment of esotropia in patients with cerebral palsy. Material and methods Seven patients were included in the study. All patients had a full ophthalmic examination on initial visit, including cycloplegic refraction and duction. The angle of esotropic deviation at distance was recorded in prism diopters. The botulinum toxin type A was administered into the medial rectus muscle under general anesthesia. Results Mean age of the patients was 12 years. The mean angle of deviation pretreatment was 36.6 PD. Successful motor alignment (orthotropia ± 10 PD) was achieved in the botulinum toxin type A group in 57.1% of patients. Conclusions The use of botulinum toxin in the treatment of esotropia in children and adolescents with cerebral palsy is an alternative to conventional surgical therapy. keywords:
children, strabismus, esotropia, botulinum toxin type A |
|
POLSKI
